The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

Bayer AG’s oral factor XIa inhibitor asundexian significantly reduced ischemic stroke by 26% in patients following a noncardioembolic ischemic stroke or high-risk transient ischemic attack in the ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Doctors know that once someone has had a stroke, the risk of a second one is much higher. In fact, nearly one in four stroke ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

In a U.S. ED observation TIA cohort, transthoracic echocardiography identified high risk cardioembolic features in nearly 1 in 5, most often patent foramen ovale and reduced LVEF.

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...